Measuring Cognitive Enhancement During Hyperbaric Oxygen Treatments

Status Completed

Clinical Trial Summary

The aim of the current study was to examine the effect of short-term HBOT (hyperbaric oxygen treatments) on a range of cognitive abilities. The current study examined whether there is a HBOT-related short-term cognitive improvement and, if so, what specific cognitive abilities are improved by the intervention.

Participants were randomized to perform cognitive tasks in one of two chambers with two different clinical environments: (a) HBOT condition: (2 ATA (atmosphere absolute) 100% oxygen for 90 minutes). (b) Control condition: in which the chamber was not pressurized (Normobaric condition- 1 ATA for 90 minutes).

Clinical Trial Description

The aim of the current study was to examine the effect of short-term HBOT on a range of cognitive abilities. The current study examined whether there is a HBOT-related short-term cognitive improvement and, if so, what specific cognitive abilities are improved by the intervention.

Participants were recruited through ads on the internet and on student social groups. All participants underwent a comprehensive physical and neurological examination, and general medical conditions were ruled out. Participants were excluded if reported changes in their cognitive or behavioral functions during one month prior to the beginning of the study. Smokers (people who smoke more than seven cigarettes a week) were required to take a lung x-ray confirming there isn't a pulmonary pathology, such as pneumothorax, pulmonary bullae, emphysema, or other lung pathologies preventing them from staying in a high ATA environment. Participants with an abnormal x-ray were excluded from the study. Participants who regularly use Methylphenidate (i.e. Ritalin) or other stimulants for attention disorders (i.e. ADHD) were instructed not to take it at the day of the experiment.

Following consent, all the participants were exposed to the testing battery in a group setting. One of the experimenters went through each of the sub-tests instructions in a detailed manner prior to a practice phase in which participants trained on the tasks. Afterwards, participants were randomized to perform the tasks in one of two chambers with two different clinical environments: (a) HBOT condition: (2 ATA 100% oxygen for 90 minutes). The atmospheric pressure in this condition was set to 2 ATA. This ATA level is known to have a clinical effect, whereas higher-pressure levels may result in inhibitory brain effects or even lead to focal toxicity (Efrati and Ben-Jacob, 2014). (b) Control condition: in which the chamber was not pressurized (Normobaric condition- 1 ATA for 90 minutes) and participants breathed air (21% oxygen). In this condition, ATA was elevated for a few minutes to 1.2 ATA in order to mimic the feeling of pressure building up in the ears. The pressure was decreased soon after to 1 ATA.

The assessment began 30 min after participants wore the oxygen masks within the chamber, in order to enable appropriate brain oxygenation in the HBOT condition (Vadas et al., 2017). The battery was composed of cognitive tests adapted for high functioning subjects and adjusted to an in-chamber group administration setting. ;

Study Design

Related Conditions & MeSH terms

Hyperbaric Oxygen Therapy

Clinical Trial Details

NCT number	NCT04358796
Study type	Interventional
Source	Assaf-Harofeh Medical Center
Contact
Status	Completed
Phase	N/A
Start date	November 10, 2017
Completion date	November 2, 2018

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT01365780` - Hyperbaric Oxygen Therapy in Distal Radius Fractures: Can it Shorten Recovery Time and Increase Fracture Healing?	N/A
Completed	`NCT05136716` - Effect of Hyperbaric Oxygen Therapy on Cerebral Palsy	N/A
Recruiting	`NCT05289700` - Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD)	Phase 3
Recruiting	`NCT05031949` - Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma	Phase 1
Recruiting	`NCT03144206` - Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study	Phase 4
Recruiting	`NCT05078073` - HBOT in the Treatment and Prevention of aGVHD	N/A
Terminated	`NCT03339037` - Hyperbaric Oxygen Therapy Effect on Post Concussion Syndrome in Children	N/A
Enrolling by invitation	`NCT02452619` - MRI Brain Changes Induced by Hyperbaric Oxygen Therapy in Brain Injury Patients	N/A
Recruiting	`NCT04311437` - Effect of Self-acupressure on Middle Ear Barotrauma Associated With Hyperbaric Oxygen Therapy	N/A
Not yet recruiting	`NCT04376359` - The Effectiveness of Hyperbaric Oxygen Therapy on Pneumonia Complicating Stroke	N/A
Completed	`NCT02619383` - HBOT Application in Erectile Dysfunction	Phase 1
Completed	`NCT03980210` - Effect of Hyperbaric Oxygen Therapy on Microcirculation	N/A
Not yet recruiting	`NCT03526796` - Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis	N/A
Completed	`NCT03615755` - Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine	N/A
Not yet recruiting	`NCT05980195` - Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.